两种联合化疗方案治疗晚期膀胱癌的临床评价及药物经济学分析  

Clinical Efficacy and Pharmacoeconomics Analysis on Two Kinds of Combination Chemotherapy Regimen for Advanced of Bladder Cancer

作　　者：林劲冠[1] 崔自重 何喆[1] 张红艳[1] 

机构地区：[1]中南大学湘雅医学院附属肿瘤医院,湖南长沙410013

出　　处：《肿瘤药学》2015年第5期357-361,共5页Anti-Tumor Pharmacy

摘　　要：目的比较顺铂联合甲氨蝶呤、长春花碱、阿霉素(MVAC)与顺铂联合吉西他滨(GC)治疗晚期膀胱癌的有效性和经济性。方法回顾性分析172例膀胱癌化疗患者,分为MVAC方案组(n=86)和GC方案组(n=86),比较两组的临床疗效,并运用成本-效果分析法进行经济学评价。结果 MVAC和GC组的临床有效率分别为52.3%与59.3%,差异无统计学意义(P>0.05)。MVAC组和GC组的成本有效率比分别为348.64和247.17,差异有统计学意义(P<0.05)。治疗过程中MVAC与GC组的不良反应均以血液系统毒性、消化道反应为主,两组间的差别无统计学意义。结论在疾病治疗方面,GC方案更具成本效果,而从疾病控制的角度看,MVAC方案更具成本效果。Objective：Objective To compare the curative effects and economy of two therapy regimens for advanced bladder cancer, which were cisplatin plus methotrexate, VLB and adriamycin （MVAC） regimen and cisplatin plus gemcitabine （GC） regimen. Methods The data were retrospectively analyzed of 172 patients with bladder cancer chemotherapy. The patients were randomly divided into MVAC group （n=86） and GC group （n=86）. After treatment, the clinical curative effects were analyzed, and their pharmacoeconomics was evaluated with the cost-effectiveness analysis method. Results The ratios of clinical curative efficacy of the MVAC and GC groups were 52.3%and 59.3%respectively, having no significant differ-ences between the two groups （P〈0.05）. The cost-efficient ratios of MVAC group and GC group were 348.64 and 247.17 respectively, and the differences were statistically significant between the two groups （P〈0.05） in this respect. The adverse reactions mainly were hematological toxicity and digestive tract reaction in both groups, and there was no statistically sig-nificant difference between them. Conclusion As for the treatment of disease, the therapeutic schedule of GC has more cost effectiveness, but the therapeutic schedule of MVAC is better in disease control.

关 键 词：晚期膀胱癌 顺铂 联合化疗 吉西他滨 药物经济学 

分 类 号：R737.1[医药卫生—肿瘤]